This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Marco Berrera: Innovator in Antisense Oligonucleotide Research
Introduction: Marco Berrera is an accomplished inventor based in Basel, Switzerland. He is currently associated with F. Hoffmann-La Roche AG, a leading global healthcare company. Although he has not yet been granted any patents, his work in the field of antisense oligonucleotides is noteworthy.
Latest Patent Applications: Marco Berrera has been involved in several significant patent applications. One of his latest applications is titled "Antisense Oligonucleotides for Modulating HTRA1 Expression." This invention relates to antisense oligonucleotides that are complementary to HTRA1, which leads to modulation of HTRA1 expression. This modulation is beneficial for a range of medical disorders, including age-related macular degeneration. Another notable application is "Oligonucleotides for Modulating RTEL1 Expression." This invention focuses on a RTEL1 inhibitor for the treatment of chronic HBV infections. It includes the use of RTEL1 inhibitors for destabilizing cccDNA, such as HBV cccDNA, and also covers antisense oligonucleotides that can reduce RTEL1 mRNA.
Conclusion: Marco Berrera is making significant contributions to the field of medical research through his innovative work on antisense oligonucleotides. His ongoing research has the potential to impact the treatment of various medical conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile